European Commission Approves Capmatinib in NSCLC With MET Exon 14 Skipping Mutation

Article

Based on results from the phase 2 GEOMETRY mono-1 trial, the European Commission has approved capmatinib for patients with non–small cell lung cancer who have MET exon 14 skipping mutations, and a need for systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.

The European Commission has approved capmatinib (Tabrecta) for adults with non–small cell lung cancer (NSCLC) who have a MET exon 14 skipping mutation and need for systemic therapy after prior treatment with immunotherapy and/or platinum-based chemotherapy, according to a press release from Novartis.1

Results from the phase 2 GEOMETRY mono-1 trial (NCT02414139) led to the approval, and patients received either capmatinib as either second-line treatment (n = 30) or later (n = 1).Among the 31 patients enrolled, the confirmed response rate (ORR) was 51.6% (95% CI, 33.1%-69.8%), with a rate of 44.0% (95% CI, 34.1%-54.3%) among those who received 1 or more prior lines of therapy.

The most common treatment-related adverse effects observed in 20% or more of the population were peripheral edema, nausea, fatigue, increased blood creatinine, vomiting, dyspnea, decreased appetite, and back pain.

“As the leading cause of cancer-related deaths worldwide, lung cancer can be a devastating diagnosis for patients and their families,” Marie-France Tschudin, president of Innovative Medicines International and chief commercial officer at Novartis, said in the press release. “With this new targeted therapy that treats a specific mutation driving cancer growth, we are delivering a much-needed treatment option and bringing hope to patients with this challenging disease.”

In May 2020, the FDA granted accelerated approval to capmatinib for patients with NSCLC who have a MET exon 14 skipping mutation, which is indicated by a FoundationOne CDx assay.2

References

  1. Novartis received European Commission approval for Tabrecta for the treatment of METex14 skipping advanced non–small cell lung cancer. News Release. Novartis. June 22, 2022. Accessed June 22, 2022. https://bit.ly/3ya8r2V
  2. FDA grants accelerated approval to capmatinib for metastatic non–small cell lung cancer. News Release. FDA. May 6, 2020. Accessed June 22, 2022. https://bit.ly/3xJGde4

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
4 experts in this video
4 experts in this video
4 experts in this video
4 experts in this video
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
4 experts in this video
Related Content